PRGOPerrigo Company plc

$14.77

The financials

Perrigo Company plc by the numbers

Perrigo Company plc (PRGO) reported revenue of $969M in Q1 2026 (quarter ended March 28, 2026), down 7.2% from the same quarter a year earlier. That came with a gross margin of 34% and net loss of $399M. For the full year FY2025, revenue was $4.25B (−2.8% year on year) and net income −$1.43B. Its largest product in 2026-Q2 was Upper Respiratory at $178M, 22% of the disclosed total, just ahead of Skin Health at 20%.

Perrigo Company plc income statement, Q1 2026 against the same quarter a year earlier
Income statementQ1 2026Q1 2025Change
Revenue$969M$1.04B−7.2%
Gross profit$326M$392M−17%
Operating income−$372M$47Mto a loss
Net income−$399M−$6.4Mn/a
Diluted EPS−$2.87−$0.05n/a
Revenue by product, 2026-Q2, as reported to the SEC
ProductRevenueShare
Upper Respiratory$178M22%
Skin Health$162M20%
Healthy Lifestyle$158M20%
Pain And Sleep$125M16%
Digestive Health$116M14%
Womens Health$65M8.1%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q2 2026Total $803.1M (+7.0%)
Womens Health grew +3.3% year on yearPain And Sleep -13% year on year
  • Upper Respiratory$178.4MQoQ -9.6%year on year -1.6%
  • Skin Health$161.8MQoQ +6.5%year on year -5.0%
  • Healthy Lifestyle$157.8MQoQ +11%year on year +2.0%
  • Pain And Sleep$124.6MQoQ +17%year on year -13%
  • Digestive Health$115.7MQoQ +20%year on year -3.4%
  • Womens Health$64.8MQoQ +18%year on year +3.3%
  • Nutrition-QoQ -year on year -
  • Oral Selfcare-QoQ -year on year -
  • Pain And Sleep Aids-QoQ -year on year -
  • Product And Service Other-QoQ -year on year -
  • Skin Care-QoQ -year on year -
  • Vitamins Minerals and Supplements-QoQ -year on year -
Segment sum = 79% of reported consolidated revenue (partial disaggregation) · Latest source: 10-Q filed 2026-08-05, SEC EDGAR